View All Attorneys

Attorneys

Dan L. O'Korn

Dan is a managing partner and his practice focuses on the business transactions important to pharmaceutical and biotech companies, including licensing and commercial transactions, FDA-related regulatory matters, asset acquisitions and divestitures, supply agreements, product development agreements and strategic alliances. Dan previously served as outside counsel to life sciences companies and in in-house counsel roles for Eli Lilly and Company, AAIPharma, Inc., Xanodyne Pharmaceuticals, Inc. and Xcellerex, Inc.

Recognition, Affiliations & Memberships

  • North Carolina State Bar
  • Pinnacle Award (Eli Lilly)
  • Corporate Business Development Award of Merit (Eli Lilly)
  • Sourcing Innovation Energizer Award (Eli Lilly)
  • American Jurisprudence Award
  • Advisory Committee, UF Sid Martin Biotechnology Institute
  • Board Member, SEBIO
  • Former Chairman, LES RTP Chapter
  • Managing Partner since 2017
  • Member, BioLabs North Carolina Advisory Board

Education

  • J.D., summa cum laude, Indiana University School of Law, 1993
  • B.A., Wabash College, 1989

Admissions

  • North Carolina
  • Indiana

Select Publications

  • When Small Pharma Buys a Big Pharma Product, North Carolina Magazine, November 2006
  • Negotiating a Manufacturing Agreement: What do you need to know?, Contract Pharma, March 2007
  • Mediummune v. Genentech and its Aftermath, Patent Strategy and Management, June 2007
  • $50 million acquisition of marketed blood pressure prescription drug franchise
  • Acquisition of marketed cardiovascular prescription drug franchise from international pharmaceutical company
  • $100 million acquisition of four branded product lines from international pharmaceutical company
  • Acquisition of two products that served as line extensions to specialty pharmaceutical company’s already existing branded product line
  • $105 million divestiture of branded multivitamin pharmaceutical product line
  • $209 million divestiture of special pharmaceutical company’s Pharmaceutical Division
  • Divestiture of Eli Lilly’s Sarafem®, a branded patented compound, in the U.S.
  • In-licensing of pharmaceutical compound combined with a co-promotion agreement with licensor
  • Worldwide out-licensing of Eli Lilly pre-clinical compound
  • $211.4 million divestiture of Darvon®/Darvocet® product line in the U.S.
  • Divestiture of Axid®, a branded, patented compound, in the U.S.
  • Negotiation of third party manufacturing agreements for active pharmaceutical ingredient and finished pharmaceutical product, and agreements for supply of critical raw materials
  • Divestiture of PCS Holding Corporation, a wholly-owned subsidiary of Eli Lilly
  • International License Agreements (Russia, Japan, S. Korea) out-licensing Phase II product technology
  • License, Development and Commercialization Agreement with international animal health company
  • License of compound in Phase II development on behalf of specialty pharma company
  • Acquisition of branded pharmaceutical from an international pharmaceutical company on behalf of specialty pharma company
  • In-licensing of vaccine technology from University Technology Transfer Office
  • Negotiation of supply chain agreements for proprietary product being reviewed for approval by FDA
  • Collaboration Agreement for development and commercialization of biopharmaceutical equipment

Recent Blog Posts